# Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

> **NCT00843349** · NA · COMPLETED · sponsor: **Myles Wolf** · enrollment: 43 (actual)

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** Lanthanum Carbonate
- **OTHER:** 900 mg Phosphate Diet
- **DRUG:** LC Placebo
- **OTHER:** Ad Libitum Diet

## Key facts

- **NCT ID:** NCT00843349
- **Lead sponsor:** Myles Wolf
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843349, "Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00843349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*